Key Takeaways
- Erin Wright of Morgan Stanley maintains Buy rating on UNH stock with $375 price objective
- UNH selected as Wright’s preferred managed care investment amid improving industry conditions
- Recent Medicare Advantage rate announcement provides enhanced clarity for 2026 payment structure
- First-quarter financial results scheduled for April 21; analyst consensus projects $6.60 EPS versus prior year’s $7.20
- Bernstein SocGen continues Outperform stance with $411 price objective on UNH stock
Morgan Stanley is expressing strong confidence in UNH ahead of its quarterly report. Erin Wright, covering the managed care sector, confirmed her Buy recommendation and $375 price objective while designating UnitedHealth as her preferred investment in the category.
UnitedHealth Group Incorporated, UNH
This endorsement follows a challenging period for the healthcare giant. Concerns surrounding Medicare Advantage performance and medical cost uncertainty have pressured UNH shares. Wright now believes these obstacles are beginning to diminish.
A primary catalyst for her increased optimism is the finalized Medicare Advantage rate announcement. This regulatory update delivered enhanced transparency regarding 2026 payment rates and strengthened expectations that UNH can continue expanding MA profitability.
Wright maintains close attention on the Optum Health transformation. Following challenges within this division, she observes mounting evidence that the unit is progressing toward sustainable improvement.
She additionally highlighted artificial intelligence-powered operational gains as a developing positive factor. Though still nascent, Wright believes UnitedHealth’s technology initiatives could substantially enhance operational performance in coming periods.
First Quarter Results Due April 21
UNH will unveil its first-quarter performance on Tuesday, April 21. Wright anticipates results largely aligned with expectations, without significant deviations in either direction.
Analyst consensus forecasts Q1 revenue reaching $109.52 billion, marginally lower than the $109.58 billion reported during the comparable 2024 period. Earnings per share are projected at $6.60, representing a decline from the previous year’s $7.20.
Market participants will scrutinize Medicare Advantage profitability trajectories, medical expense updates, and management commentary regarding Optum Health’s stabilization. Artificial intelligence efficiency developments and full-year guidance will attract additional attention.
UNH currently changes hands at $316.40. Based on this valuation, Morgan Stanley’s $375 target represents approximately 18.5% potential appreciation.
Bernstein Expresses Greater Optimism
Bernstein SocGen demonstrates even stronger conviction. Analyst Lance Wilkes reaffirmed an Outperform recommendation and $411 price target, characterizing UNH’s current valuation as compelling.
The research firm anticipates broader industry improvement as Medicare Advantage profitability rebounds from recent lows following rate adjustments and competitive exits.
Bernstein also identifies company-specific margin enhancement as UNH discontinues underperforming MA and Optum Health offerings. The firm forecasts robust earnings-per-share expansion throughout the next four-year period.
The equity trades at a price-to-earnings multiple of 24. For perspective, the consensus Wall Street price target across 18 Buy and 5 Hold recommendations stands at $366.24—suggesting approximately 15.75% appreciation from present levels.
One consideration merits attention: Leerink identified that UNH confronts potential impact from expanded RADV compliance reviews by CMS. Sixty contracts representing 92% of its Medicare Advantage enrollment are currently under examination—a substantial increase from zero in 2018. These assessments commenced processing during April 2025.
UBS recently incorporated UNH into its Global High-Quality Dividend Stock List, recognizing it as a dependable dividend-paying investment.
